Evidence map›Paper›PMID 42814808›Full record

ArticleScience advances2026

Multiobjective V

Max D Overath, Suthimon Thumtecho, Esperanza Rivera-de-Torre, Melisa Benard-Valle, Darian S Wolff, Rahmat Grahadi, Kasper H Björnsson, Andreas S H Rygaard, Nils Hofmann, Jann Ledergerber and 5 more

Abstract read
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Max D OverathDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0009-0009-6347-9809
Suthimon ThumtechoDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0000-0002-8853-6568
Esperanza Rivera-de-TorreDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0000-0002-0272-6150
Melisa Benard-ValleDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0000-0002-0042-6592
Darian S WolffDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0000-0002-9266-3017
Rahmat GrahadiDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0000-0003-1904-1163
Kasper H BjörnssonDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0000-0003-1339-8620
Andreas S H RygaardDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.
Nils HofmannDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0009-0006-4639-6161
Jann LedergerberDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0009-0004-9774-095X
Anne LjungarsDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0000-0002-2158-0601
Andreas H LaustsenDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0000-0001-6918-5574
Simon OlssonDepartment of Computer Science and Engineering, Chalmers University of Technology and University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-3927-7897
Thomas J FryerIMES, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0003-4338-0405
Timothy P JenkinsDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0000-0003-2979-5663

Funding

Wellcome Trust
6 · The paper itself

Abstract

Finding therapeutic antibodies that bind multiple related targets with high affinity and favorable biophysical properties remains challenging and resource-intensive. For snakebite antivenoms, this challenge is critical as treatments must neutralize toxins across multiple snake species. We developed a pipeline combining high-throughput yeast screening, deep sequencing, and AlphaFold3 structure prediction to identify polyspecific variable domains of heavy chain-only antibodies (V

Indexed as

High-Throughput Screening AssaysImmunoglobulin Heavy ChainsAnimalsModels, MolecularProtein BindingImmunoglobulin Heavy Chains

Identifiers

PMID42814808
PMCPMC13626040

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.